UnitedHealth Group reported strong Q2 results with adjusted EPS rising nearly 30% and improved operating margins. The company raised its 2026 adjusted EPS guidance to $19.50–20.00 and increased its operating cash flow forecast by $6 billion, showing confidence in future growth. Additionally, UnitedHealth is accelerating its share buyback program, doubling the full-year target to $5 billion due to perceived undervaluation. Analysts maintain a 'Buy' rating, expecting a 38–39% upside in the next 12–16 months driven by earnings growth and margin recovery.
UnitedHealth Group reported strong second-quarter earnings, raised its guidance, and doubled its stock buyback authorization, reinforcing its Buy rating. The company benefits from a market shift favoring defensive healthcare stocks over AI-focused on...
The Schwab U.S. Dividend Equity ETF (SCHD) is recommended as a Buy due to its mix of high-quality dividend-paying stocks like ABT, UNH, and MRK, which offer strong dividend growth and underappreciated catalysts. The fund's defensive sector focus and ...
Health stocks Eli Lilly (LLY), United Health Group (UNH), and Merck (MRK) have recently seen positive developments, including drug approvals and strong earnings. These gains have boosted their stock prices, with LLY up over 8% YTD, UNH up 25.8% YTD, ...
